Recent 8-K filings for WGS

• May 4, 2026, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  GeneDx Q1 revenue $102.3M (+17% YoY); exome/genome volume +34%; FY guidance $475-490M

  Q1 revenue $102.3M (+17% YoY); exome/genome revenue $90.6M (+27% YoY).

• March 2, 2026, 6:59 PM ET debt materiality 0.65 neutral item 1.01item 1.02item 2.03 ◈ Material Agreements ×2◈ Debt Financings

  GeneDx enters $100M term loan with Blackstone to repay existing credit facility

  $100M term loan funded Feb 27, 2026; proceeds used to repay existing Perceptive Credit term loan.

• February 23, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  GeneDx Q4 revenue $121M, +27% YoY; exome/genome +32%; reaffirms FY2026 guidance $540-555M

  Q4 revenue $121M (+27% YoY); exome/genome revenue $104M (+32%, or +42% ex one-time).

• January 12, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  GeneDx prelim FY2025 rev $427M (+41%); FY2026 guidance $540-555M

  FY2025 exome/genome revenue ~$360M (+54% YoY); Q4 $104M (+32% YoY).

• October 28, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  GeneDx Q3 2025 revenue $116.7M (+52% YoY), adjusted net income $14.7M; raises full-year guidance

  Q3 revenue $116.7M (+52% YoY); exome/genome revenue $98.9M (+65% YoY).

• July 29, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  GeneDx Q2 revenue $102.7M (+49% YoY); raises FY outlook to $400-415M

  Exome/genome test revenue $85.9M (+69% YoY) on volume of 23,102 results (+28%).

• April 30, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  GeneDx Q1 revenue $87.1M, exome/genome revenue up 62% YoY; raises FY 2025 guidance

  Q1 exome/genome revenue $71.4M (+62% YoY); total revenue $87.1M (+42% YoY).

• April 16, 2025, 7:59 PM ET M&A materiality 0.80 positive item 1.01item 3.02item 7.01item 9.01

  GeneDx to acquire Fabric Genomics for up to $51M; expands AI genomic interpretation globally

  GeneDx will pay $33M cash at closing for Fabric Genomics; total consideration up to $51M based on milestone achievements (2025/2026 revenue and margin targets).

• February 18, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  GeneDx Q4 revenue up 64% YoY to $95.3M; adjusted net income $16.8M; FY2025 guidance $350-360M

  Q4 revenues $95.3M (+64% YoY); exome/genome revenue $78.8M (+101% YoY).

• January 13, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 7.01item 9.01

  GeneDx reports prelim FY2024 revenue ≥$299M (+54% YoY), above prior guidance

  Preliminary FY2024 revenue at least $299M (+54% YoY), above prior guidance of $284-290M.

• October 29, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  GeneDx achieves Q3 2024 profitability with $1.2M adjusted net income, raises FY guidance

  Revenue $76.6M (+52% YoY); exome/genome revenue $60.0M (+77% YoY).

• July 30, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  GeneDx Q2 revenue $68.9M (+52% YoY); raises FY24 revenue guidance to $255-265M

  Exome/genome test revenue $50.7M (+77% YoY), volume 18,017 (+52% YoY).

• April 29, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  GeneDx Q1 exome/genome revenue up 96% YoY; raises FY 2024 guidance to $235-245M

  Revenue from continuing ops $61.5M (+51% YoY); exome/genome revenue $44.0M (+96% YoY).

• April 29, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01 ◈ Material Agreements

  GeneDx enters $75M at-the-market equity offering agreement with TD Securities

  Company may sell up to $75M of Class A common stock through TD Cowen as agent.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.75 · Most common event earnings

11 positive 0 negative 7 neutral

source · WGS on sec.gov